Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

U.S. Healthtech Industry Analysis

UpdatedJun 13, 2026
DataAggregated Company Financials
Companies70
  • 7D-4.4%
  • 3M-6.5%
  • 1Y-45.4%
  • YTD-28.0%

Over the last 7 days, the Healthtech industry has dropped 4.4%, driven by a pullback from Veeva Systems of 7.6%. Meanwhile, HeartFlow actually outperformed within the industry, gaining 18% in the last week. However, the industry is down 45% over the past year. Looking forward, earnings are forecast to grow by 23% annually.

Industry Valuation and Performance

Has the U.S. Healthtech Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Sat, 13 Jun 2026US$45.0bUS$14.4b-US$755,064,816.0028x-59.6x3.1x
Mon, 11 May 2026US$47.8bUS$13.6b-US$369,312,811.0031.2x-129.5x3.5x
Wed, 08 Apr 2026US$47.1bUS$13.6b-US$416,162,415.0031.9x-113.1x3.5x
Fri, 06 Mar 2026US$51.5bUS$13.6b-US$321,446,340.0040.5x-160.1x3.8x
Sun, 01 Feb 2026US$57.4bUS$13.6b-US$102,102,340.0045.7x-562.6x4.2x
Tue, 30 Dec 2025US$64.5bUS$13.6b-US$102,572,340.0053.6x-628.6x4.7x
Thu, 27 Nov 2025US$70.0bUS$13.6b-US$117,958,271.0055.4x-593.2x5.2x
Sat, 25 Oct 2025US$80.5bUS$13.1b-US$212,082,154.0059.3x-379.4x6.1x
Mon, 22 Sep 2025US$78.6bUS$13.2b-US$266,647,296.0058x-294.8x5.9x
Wed, 20 Aug 2025US$78.1bUS$13.1b-US$369,126,795.0059.5x-211.5x6x
Fri, 18 Jul 2025US$78.4bUS$13.2b-US$1,452,848,447.0057.9x-54x5.9x
Sun, 15 Jun 2025US$76.8bUS$13.2b-US$1,383,488,447.0055.9x-55.5x5.8x
Tue, 13 May 2025US$70.4bUS$13.1b-US$1,464,283,959.0057.8x-48.1x5.4x
Thu, 10 Apr 2025US$61.8bUS$13.2b-US$1,414,656,089.0051.8x-43.7x4.7x
Sat, 08 Mar 2025US$71.6bUS$13.1b-US$1,519,804,514.0059.6x-47.1x5.4x
Mon, 03 Feb 2025US$71.5bUS$12.9b-US$1,638,054,514.0060.1x-43.6x5.6x
Wed, 01 Jan 2025US$65.2bUS$12.9b-US$1,636,315,514.0053.7x-39.9x5.1x
Fri, 29 Nov 2024US$67.7bUS$12.8b-US$1,712,780,390.0058.5x-39.5x5.3x
Sun, 27 Oct 2024US$62.7bUS$13.6b-US$3,127,204,656.0049.5x-20x4.6x
Tue, 24 Sep 2024US$65.8bUS$14.0b-US$3,302,096,821.0055.8x-19.9x4.7x
Thu, 22 Aug 2024US$61.2bUS$13.9b-US$3,360,989,829.0057.9x-18.2x4.4x
Sat, 20 Jul 2024US$57.4bUS$13.7b-US$1,860,692,542.0052.6x-30.8x4.2x
Mon, 17 Jun 2024US$58.0bUS$13.7b-US$1,889,788,216.0047.2x-30.7x4.2x
Wed, 15 May 2024US$56.8bUS$12.8b-US$1,993,178,215.0049.3x-28.5x4.5x
Fri, 12 Apr 2024US$60.7bUS$12.7b-US$1,616,515,745.0050.4x-37.6x4.8x
Sun, 10 Mar 2024US$64.8bUS$14.1b-US$1,445,414,794.0050.5x-44.8x4.6x
Tue, 06 Feb 2024US$60.0bUS$13.8b-US$5,690,204,752.0058x-10.5x4.4x
Thu, 04 Jan 2024US$69.8bUS$18.3b-US$5,781,192,665.0052.8x-12.1x3.8x
Sat, 02 Dec 2023US$65.0bUS$18.2b-US$5,807,346,665.0053.2x-11.2x3.6x
Mon, 30 Oct 2023US$64.6bUS$18.1b-US$5,527,928,965.0048.8x-11.7x3.6x
Wed, 27 Sep 2023US$68.5bUS$18.0b-US$5,514,972,389.0050.7x-12.4x3.8x
Fri, 25 Aug 2023US$69.0bUS$17.9b-US$5,554,149,562.0050.4x-12.4x3.8x
Sun, 23 Jul 2023US$78.2bUS$17.7b-US$8,580,548,318.0060.9x-9.1x4.4x
Tue, 20 Jun 2023US$76.1bUS$17.7b-US$8,581,046,209.0062.9x-8.9x4.3x
Price to Earnings Ratio

-8.9x


Total Market Cap: US$76.1bTotal Earnings: -US$8,581,046,209.00Total Revenue: US$17.7bTotal Market Cap vs Earnings and Revenue0%0%0%
U.S. Healthtech Industry Price to Earnings3Y Average -130.9x202420252026
Current Industry PE
  • Investors are pessimistic on the American Healthcare Services industry, indicating that they anticipate long term growth rates will be lower than they have historically.
  • The 3-year average PS ratio of 4.7x is higher than the industry's current PS ratio of 3.1x.
Past Earnings Growth
  • The earnings for companies in the Healthcare Services industry have improved over the last three years.
  • Meanwhile revenues for these companies have declined 6.7% per year.
  • This means that less sales are being generated overall, but since the cost of doing business is lower, losses have been shrinking.

Industry Trends

Which industries have driven the changes within the U.S. Healthcare industry?

US Market0.81%
Healthcare0.85%
Healthtech-4.36%
Healthtech-4.36%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
HTFL HeartFlowUS$33.2418.3%
+US$443.3m		n/aPS15x
CTEV ClaritevUS$30.8919.5%
+US$86.1m		-16.8%PS0.5x
EVH Evolent HealthUS$4.8013.7%
+US$65.2m		-42.0%PS0.3x
TDOC Teladoc HealthUS$7.344.1%
+US$52.3m		7.0%PS0.5x
HSTM HealthStreamUS$26.133.5%
+US$26.0m		-4.1%PE38.3x

Latest News

DOCS
US$20.04
Doximity
7D
-2.7%
1Y
-64.2%
AMWL
US$9.11
American Well
7D
5.7%
1Y
34.4%
VEEV
US$159.54
Veeva Systems
7D
-7.6%
1Y
-43.5%
HSTM
US$26.13
HealthStream
7D
3.5%
1Y
-4.1%
PHR
US$9.06
Phreesia
7D
-5.0%
1Y
-65.1%
HTFL
US$33.24
HeartFlow
7D
18.3%
1Y
n/a
CTEV
US$30.89
Claritev
7D
19.5%
1Y
-16.8%
Narrative Update • Jun 11

CTEV: New Contracts And Management Changes Will Drive Future Upside Potential

Claritev's updated analyst price target has moved lower by about $3 to $36.83, as analysts factor in slightly softer revenue growth assumptions, a modestly higher discount rate, and a lower future P/E multiple. This is partly offset by higher projected profit margins and recent Street targets that range from $32 to $61.
LFMD
US$4.70
LifeMD
7D
-3.9%
1Y
-62.3%
Seeking Alpha • Jun 09

LifeMD: A Growing Healthcare Tech Stock, As Q1 Results Confirm Patient Demand

Summary LifeMD offers a compelling growth opportunity, driven by digital healthcare tailwinds and record net subscriber additions in Q1. LFMD trades at a significant valuation discount, with fwd EV/Sales of 0.94x and a Wall St. price target implying 102% upside. Despite strong revenue growth, LFMD faces near-term earnings pressure from elevated marketing spend and negative operating income. LFMD's integrated pharmacy network and cash-rich balance sheet enhance its competitive positioning, but weak ROE and profitability remain key risks. The company has a cash runway of about 8.2 years under current scenario, where debt payments are a major cash impact, despite operating cashflow being positive. Read the full article on Seeking Alpha
TDOC
US$7.34
Teladoc Health
7D
4.1%
1Y
7.0%
ITOC
US$0.34
iTonic Holdings
7D
21.4%
1Y
-98.0%
SOPH
US$4.88
SOPHiA GENETICS
7D
-2.4%
1Y
70.0%
WAY
US$18.75
Waystar Holding
7D
-6.3%
1Y
-51.8%
Narrative Update • Jun 06

WAY: AI Automation And Buybacks Will Support Future Earnings Rerating

Analysts have slightly reduced their price target for Waystar Holding to $33.83 from $34.26, indicating a modest adjustment in fair value and future P/E assumptions while keeping revenue growth and profit margin expectations broadly consistent with previous estimates. What's in the News Waystar reported strong Q1 2026 results that surpassed revenue and earnings estimates, and reaffirmed full year 2026 revenue guidance in the range of US$1.274b to US$1.294b, according to recent earnings coverage.
SLP
US$16.32
Simulations Plus
7D
2.8%
1Y
-14.4%
Narrative Update • Jun 06

SLP: AI Partnerships And Steady Guidance Will Shape Balanced Long Term Outlook

Analysts have reiterated a $16.00 price target for Simulations Plus, citing updated assumptions around discount rates, revenue growth, profit margins, and P/E expectations as the basis for keeping their view steady. What's in the News Simulations Plus announced a technical collaboration with NVIDIA to bring GPU acceleration and AI-assisted workflows into its PBPK, PK/PD, and QSP modeling engines, with the aim of speeding up complex drug development simulations and broadening the use of virtual population studies.
CERT
US$5.20
Certara
7D
-3.2%
1Y
-52.8%
Narrative Update • Jun 04

CERT: Biosimulation Partnerships And Model Informed Development Will Support Long Term Relevance

Analysts have reduced the Certara price target by $1.10, reflecting updated views on fair value, revenue growth, and profitability assumptions following recent research updates from several firms. Analyst Commentary Recent research updates show a broad reset in expectations around Certara, with several firms trimming price targets and reassessing how current execution lines up with prior growth assumptions.
EVH
US$4.80
Evolent Health
7D
13.7%
1Y
-42.0%
Narrative Update • Jun 01

EVH: Higher Margin Outlook And 2026 Earnings Guidance Will Support Future Upside

Analysts have lifted their price target on Evolent Health to $5.50 from $4.00, citing updated assumptions that include higher projected revenue growth, a wider profit margin, and a lower future P/E multiple in their models. Analyst Commentary Bullish analysts have recently highlighted Evolent Health as a stock where revised assumptions on revenue, margins, and valuation multiples support a higher potential share price.
ONMD
US$0.54
OneMedNet
7D
-19.7%
1Y
68.5%